Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD)

There will be 4 groups of treatment; each group will consist of 20 subjects with the treatment regimens for 12 weeks:

Treatment I : 1 caplet of Proliverenol 500 mg twice daily Treatment II : 2 caplets of Proliverenol 500 mg once daily Treatment III : 2 caplets of Proliverenol 500 mg twice daily Treatment IV : 2 caplets of Placebo daily

Study subjects will be asked to come to the clinic every 4-week interval throughout the study period.

Subjects will be evaluated for treatment efficacy at baseline and at interval of 4 weeks over the 12-week course of therapy. Throughout the 12-week therapy, subjects should record the product consumption and adverse event occurred during the study in the provided Patient's Diary.

The safety profile of study medication other than vital signs and adverse event will be measured at baseline and end of study.

Inclusion criteria

• Signed informed consent
• Male or female subjects with age of 18 years or older at screening.
• Diagnosed as NAFLD with liver ultrasonography (USG). Patients with bright liver appearance based on USG, will be followed by CAP examination. Steatosis is defined if CAP >263 dB/m
• Presence of hepatic impairment, defined as any of serum ALT level > ULN
• Able to take oral medication.

Exclusion criteria

• Suspected positive COVID-19 based on clinical symptoms or SARS-COV-2 antigen test
• Pregnancy and lactation period.
• Suspected alcoholic liver disease
• History of or presence of autoimmune liver diseases
• Presence of Bilirubin level > 2x ULN
• Uncontrolled Diabetes Mellitus with HbA1c ≥ 9.0%
• History or presence of significant/advanced CV, metabolic, acute or chronic infectious diseases, including viral hepatitis (B and C), or malignancy.
• Suspected cirrhosis as supported by biochemical profile (PLT count, albumin)
• Presence of severe renal dysfunction
• Current or regular use of drug-induced hepatotoxicity, such as: such as non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, anti-epileptic drugs (e.g. carbamazepines, phenytoin, barbiturates), or anti-tuberculous drugs other than the investigational product
• Current or regular use of herbal medicines with hepato-protective properties
• Known or suspected hypersensitivity to the trial product or related products